Literature DB >> 21148332

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.

Rachael A Clark1, Jeffrey B Shackelton, Rei Watanabe, Adam Calarese, Kei-ichi Yamanaka, James J Campbell, Jessica E Teague, Helen P Kuo, DirkJan Hijnen, Thomas S Kupper.   

Abstract

In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are confined to skin and are difficult to isolate and discriminate from benign reactive cells. We found that T cells from CTCL skin lesions contained a population of large, high-scatter, activated skin homing T cells not observed in other inflammatory skin diseases. High-scatter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contained only clonal T cells in patients with identifiable malignant Vβ clones. T(HS) cells were present in the blood of patients with leukemic CTCL, absent in patients without blood involvement, and contained only clonal malignant T cells. The presence of clonal T(HS) cells correlated with skin disease in patients followed longitudinally. Clonal T(HS) cells underwent apoptosis in patients clearing on extracorporeal photopheresis but persisted in nonresponsive patients. Benign clonal T-cell proliferations mapped to the normal low-scatter T-cell population. Thus, the malignant T cells in both MF and leukemic CTCL can be conclusively identified by a unique scatter profile. This observation will allow selective study of malignant T cells, can be used to discriminate patients with MF from patients with other inflammatory skin diseases, to detect peripheral blood involvement, and to monitor responses to therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148332      PMCID: PMC3056643          DOI: 10.1182/blood-2010-05-287664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.

Authors:  J A Hoxie; J D Alpers; J L Rackowski; K Huebner; B S Haggarty; A J Cedarbaum; J C Reed
Journal:  Science       Date:  1986-11-28       Impact factor: 47.728

Review 2.  Immune dysregulation in atopic dermatitis.

Authors:  Michele Miraglia del Giudice; Fabio Decimo; Salvatore Leonardi; Nunzia Maioello; Raffaele Amelio; Antonella Capasso; Carlo Capristo; Angelo F Capristo
Journal:  Allergy Asthma Proc       Date:  2006 Nov-Dec       Impact factor: 2.587

3.  Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE).

Authors:  G S Wood; R M Tung; A C Haeffner; C F Crooks; S Liao; R Orozco; H Veelken; M E Kadin; H Koh; P Heald
Journal:  J Invest Dermatol       Date:  1994-07       Impact factor: 8.551

4.  Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis.

Authors:  H Pilch; H Höhn; K Freitag; C Neukirch; A Necker; P Haddad; B Tanner; P G Knapstein; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 5.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

6.  Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.

Authors:  Katalin Ferenczi; Nikhil Yawalkar; David Jones; Thomas S Kupper
Journal:  Arch Dermatol       Date:  2003-07

Review 7.  Skin-resident T cells: the ups and downs of on site immunity.

Authors:  Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-08-13       Impact factor: 8.551

8.  Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome.

Authors:  Jessica Shin; Stefano Monti; Daniel J Aires; Madeleine Duvic; Todd Golub; David A Jones; Thomas S Kupper
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

9.  Aberrant expression of T-plastin in Sezary cells.

Authors:  Ming-wan Su; Irene Dorocicz; Wieslawa H Dragowska; Vincent Ho; Gang Li; Nicolas Voss; Randy Gascoyne; Youwen Zhou
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 10.  Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects.

Authors:  Scott H Sicherer; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2007-04-06       Impact factor: 10.793

View more
  16 in total

1.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

2.  Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Dina Stroopinsky; Li Yin; Jacalyn Rosenblatt; Maroof Alam; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Kristen Palmer; Maxwell D Coll; Hasan Rajabi; Athalia Pyzer; Michal Bar-Natan; Katarina Luptakova; Jon Arnason; Robin Joyce; Donald Kufe; David Avigan
Journal:  Blood       Date:  2015-06-05       Impact factor: 22.113

Review 3.  Cutaneous T-cell Lymphoma.

Authors:  Melissa Pulitzer
Journal:  Clin Lab Med       Date:  2017-09       Impact factor: 1.935

4.  Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.

Authors:  Nicholas Borcherding; Andrew P Voigt; Vincent Liu; Brian K Link; Weizhou Zhang; Ali Jabbari
Journal:  Clin Cancer Res       Date:  2019-02-04       Impact factor: 12.531

5.  Single-cell heterogeneity in Sézary syndrome.

Authors:  Terkild Brink Buus; Andreas Willerslev-Olsen; Simon Fredholm; Edda Blümel; Claudia Nastasi; Maria Gluud; Tengpeng Hu; Lise M Lindahl; Lars Iversen; Hanne Fogh; Robert Gniadecki; Ivan V Litvinov; Jenny L Persson; Charlotte Menné Bonefeld; Carsten Geisler; Jan Pravsgaard Christensen; Thorbjørn Krejsgaard; Thomas Litman; Anders Woetmann; Niels Ødum
Journal:  Blood Adv       Date:  2018-08-28

Review 6.  The biomarker landscape in mycosis fungoides and Sézary syndrome.

Authors:  Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-02-02       Impact factor: 3.960

7.  Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.

Authors:  Duncan Murray; Jack Luke McMurray; Suzy Eldershaw; Hayden Pearce; Nathaniel Davies; Julia J Scarisbrick; Paul Moss
Journal:  Blood Adv       Date:  2019-02-26

8.  Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.

Authors:  Pedro Horna; Lynn C Moscinski; Lubomir Sokol; Haipeng Shao
Journal:  Cytometry B Clin Cytom       Date:  2018-10-16       Impact factor: 3.058

Review 9.  The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Ronnie M Abraham; Qian Zhang; Niels Odum; Mariusz A Wasik
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

10.  Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Authors:  Salvia Jain; Abigail Washington; Rebecca Karp Leaf; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Dina Stroopinsky; Athalia Pyzer; Leandra Cole; Myrna Nahas; Arie Apel; Jacalyn Rosenblatt; Jon Arnason; Donald Kufe; David Avigan
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.